Variable susceptibility to piperacillin/tazobactam amongst Klebsiella spp. with extended-spectrum beta-lactamases.

MICs of piperacillin/tazobactam are conventionally determined by varying the concentration of piperacillin in the presence of a fixed 4 mg/L tazobactam. When tested in this way, the MIC distribution for Klebsiella isolates with extended-spectrum beta-lactamases (ESBLs) is strongly bimodal, such that many producers are inhibited at 16 + 4 mg/L whilst others require MICs of > or =512 + 4 mg/L. When, however, piperacillin/tazobactam was tested as a fixed 8:1 ratio, the MIC distribution became unimodal. If clavulanate 4 mg/L was combined with piperacillin, a unimodal MIC distribution was seen for ESBL-producing Klebsiella spp. but a bimodal distribution arose if the clavulanate concentration was reduced to 0.25 mg/L. These data for alternative combinations suggested that the bimodal MIC distribution seen for piperacillin + tazobactam 4 mg/L was a titration effect, not a reflection of some ESBLs being resistant to tazobactam. Even within single strains, as defined by serotype and DNA fingerprints, there was considerable variation in susceptibility to piperacillin + tazobactam 4 mg/L, with some representatives highly susceptible and others highly resistant. Some of the more resistant representatives produced more of their ESBL, or had a greater number of beta-lactamase types, but these associations were not universal. Elevated resistance to piperacillin + tazobactam was not associated with porin change in any ESBL producer examined, but has been found by others.

[1]  G. Paul,et al.  Dissemination in five French hospitals ofKlebsiella pneumoniae serotype K25 harbouring a new transferable enzymatic resistance to third generation cephalosporins and aztreonam , 1988, European Journal of Clinical Microbiology and Infectious Diseases.

[2]  D. Livermore,et al.  Detection of β-lactamase-mediated resistance , 2001 .

[3]  D. Livermore,et al.  Complexity and Diversity of Klebsiella pneumoniae Strains with Extended-Spectrum β-Lactamases Isolated in 1994 and 1996 at a Teaching Hospital in Durban, South Africa , 2001, Antimicrobial Agents and Chemotherapy.

[4]  D. Livermore,et al.  Antimicrobial resistance amongst Klebsiella spp. collected from intensive care units in Southern and Western Europe in 1997-1998. , 2000, The Journal of antimicrobial chemotherapy.

[5]  L. Rice,et al.  High-Level Expression of Chromosomally Encoded SHV-1 β-Lactamase and an Outer Membrane Protein Change Confer Resistance to Ceftazidime and Piperacillin- Tazobactam in a Clinical Isolate of Klebsiella pneumoniae , 2000, Antimicrobial Agents and Chemotherapy.

[6]  D. Paterson,et al.  Fatal infection due to extended-spectrum beta-lactamase-producing Escherichia coli: implications for antibiotic choice for spontaneous bacterial peritonitis. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[7]  T. Pitt,et al.  Epidemiological typing of klebsiellae with extended-spectrum beta-lactamases from European intensive care units. , 1998, The Journal of antimicrobial chemotherapy.

[8]  R. Gautom Rapid pulsed-field gel electrophoresis protocol for typing of Escherichia coli O157:H7 and other gram-negative organisms in 1 day , 1997, Journal of clinical microbiology.

[9]  D. Livermore,et al.  Antibiotic resistance and production of extended-spectrum beta-lactamases amongst Klebsiella spp. from intensive care units in Europe. , 1996, The Journal of antimicrobial chemotherapy.

[10]  L. Rice,et al.  Molecular genetics of resistance to both ceftazidime and beta-lactam-beta-lactamase inhibitor combinations in Klebsiella pneumoniae and in vivo response to beta-lactam therapy. , 1996, The Journal of infectious diseases.

[11]  G. Jacoby,et al.  A functional classification scheme for beta-lactamases and its correlation with molecular structure , 1995, Antimicrobial agents and chemotherapy.

[12]  L. Rice,et al.  In vivo efficacies of beta-lactam-beta-lactamase inhibitor combinations against a TEM-26-producing strain of Klebsiella pneumoniae , 1994, Antimicrobial Agents and Chemotherapy.

[13]  P. Lagrange,et al.  Molecular epidemiology of Klebsiella pneumoniae strains that produce SHV-4 beta-lactamase and which were isolated in 14 French hospitals , 1994, Journal of clinical microbiology.

[14]  L. Gutmann,et al.  Different ratios of the piperacillin-tazobactam combination for treatment of experimental meningitis due to Klebsiella pneumoniae producing the TEM-3 extended-spectrum beta-lactamase , 1994, Antimicrobial Agents and Chemotherapy.

[15]  D. Livermore,et al.  Activity of cefepime and other beta-lactam antibiotics against permeability mutants of Escherichia coli and Klebsiella pneumoniae. , 1993, The Journal of antimicrobial chemotherapy.

[16]  D. Livermore Determinants of the activity of β-lactamase inhibitor combinations , 1993 .

[17]  Claude Carbón,et al.  Piperacillin, tazobactam, and gentamicin alone or combined in an endocarditis model of infection by a TEM-3-producing strain of Klebsiella pneumoniae or its susceptible variant , 1992, Antimicrobial Agents and Chemotherapy.

[18]  D. Livermore,et al.  Activity of clavulanate combinations against TEM-1 beta-lactamase-producing Escherichia coli isolates obtained in 1982 and 1989. , 1991, The Journal of antimicrobial chemotherapy.

[19]  Y. Chabbert,et al.  Selection and characterization of beta-lactam-resistant Escherichia coli K-12 mutants , 1983, Antimicrobial Agents and Chemotherapy.

[20]  O. H. Lowry,et al.  Protein measurement with the Folin phenol reagent. , 1951, The Journal of biological chemistry.